Compare · DRNA vs MYOS
DRNA vs MYOS
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and MYOS RENS Technology Inc. (MYOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and MYOS operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for MYOS).
- Company
- Dicerna Pharmaceuticals, Inc.
- MYOS RENS Technology Inc.
- Price
- $38.23+0.61%
- -
- Market cap
- $2.96B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 0
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest MYOS
- MedAvail and MYOS RENS Technology Announce Closing of Business Combination
- MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding
- MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger
- MYOS RENS Technology Announces Net Revenues Increase 39% for the Three Months Ended September 30, 2020
- INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - MVC, ARA, YIN, MYOS